Delta Variant Spike RBD SARS-CoV-2

Product Description

Delta Variant Spike RBD SARS-CoV-2
Catalog number: B2010480
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 100 ug
Molecular Weight or Concentration: 27 kDa
Supplied as: Lyophilized powder
Appearance: Powder
Applications: highly pure (> 95%) SARS-CoV-2 RBD of the Delta Variant. This protein was expressed in HEK293 and has been tested for its ability to bind the human cellular receptor ACE2.
Storage: -20C
Keywords: Delta RBD, Delta Spike
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

Download SARS-CoV-2 Brochure

References:
1: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JC, Muecksch F,
Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,
Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,
Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies
by SARS-CoV-2 spike protein variants. Elife. 2020 Oct 28;9:e61312.

2: Weisblum Y, Schmidt F, Zhang F, DaSilva J, Poston D, Lorenzi JCC, Muecksch F,
Rutkowska M, Hoffmann HH, Michailidis E, Gaebler C, Agudelo M, Cho A, Wang Z,
Gazumyan A, Cipolla M, Luchsinger L, Hillyer CD, Caskey M, Robbiani DF, Rice CM,
Nussenzweig MC, Hatziioannou T, Bieniasz PD. Escape from neutralizing antibodies
by SARS-CoV-2 spike protein variants. bioRxiv [Preprint]. 2020 Jul
22:2020.07.21.214759.

3: Zhou Y, Liu Z, Li S, Xu W, Zhang Q, Silva IT, Li C, Wu Y, Jiang Q, Liu Z,
Wang Q, Guo Y, Wu J, Gu C, Cai X, Qu D, Mayer CT, Wang X, Jiang S, Ying T, Yuan
Z, Xie Y, Wen Y, Lu L, Wang Q. Enhancement versus neutralization by SARS-CoV-2
antibodies from a convalescent donor associates with distinct epitopes on the
RBD. Cell Rep. 2021 Feb 2;34(5):108699.

4: McCallum M, Marco A, Lempp F, Tortorici MA, Pinto D, Walls AC, Beltramello M,
Chen A, Liu Z, Zatta F, Zepeda S, di Iulio J, Bowen JE, Montiel-Ruiz M, Zhou J,
Rosen LE, Bianchi S, Guarino B, Fregni CS, Abdelnabi R, Caroline Foo SY,
Rothlauf PW, Bloyet LM, Benigni F, Cameroni E, Neyts J, Riva A, Snell G, Telenti
A, Whelan SPJ, Virgin HW, Corti D, Pizzuto MS, Veesler D. N-terminal domain
antigenic mapping reveals a site of vulnerability for SARS-CoV-2. bioRxiv
[Preprint]. 2021 Jan 14:2021.01.14.426475.

5: Chakraborty S. Evolutionary and structural analysis elucidates mutations on
SARS-CoV2 spike protein with altered human ACE2 binding affinity. Biochem
Biophys Res Commun. 2021 Jan 1;534:374-380.

6: Zahradník J, Marciano S, Shemesh M, Zoler E, Harari D, Chiaravalli J, Meyer
B, Rudich Y, Li C, Marton I, Dym O, Elad N, Lewis MG, Andersen H, Gagne M, Seder
RA, Douek DC, Schreiber G. SARS-CoV-2 variant prediction and antiviral drug
design are enabled by RBD in vitro evolution. Nat Microbiol. 2021 Aug 16.

7: Kim S, Liu Y, Lei Z, Dicker J, Cao Y, Zhang XF, Im W. Differential
Interactions Between Human ACE2 and Spike RBD of SARS-CoV-2 Variants of Concern.
bioRxiv [Preprint]. 2021 Jul 26:2021.07.23.453598.

8: Carnell GW, Ciazynska KA, Wells DA, Xiong X, Aguinam ET, McLaughlin SH,
Mallery D, Ebrahimi S, Ceron-Gutierrez L, Asbach B, Einhauser S, Wagner R, James
LC, Doffinger R, Heeney JL, Briggs JAG. SARS-CoV-2 Spike Protein Stabilized in
the Closed State Induces Potent Neutralizing Responses. J Virol. 2021 Jul
12;95(15):e0020321.

9: Shen X, Tang H, McDanal C, Wagh K, Fischer W, Theiler J, Yoon H, Li D, Haynes
BF, Sanders KO, Gnanakaran S, Hengartner N, Pajon R, Smith G, Dubovsky F, Glenn
GM, Korber B, Montefiori DC. SARS-CoV-2 variant B.1.1.7 is susceptible to
neutralizing antibodies elicited by ancestral Spike vaccines. bioRxiv
[Preprint]. 2021 Jan 29:2021.01.27.428516.
10: Martínez-Flores D, Zepeda-Cervantes J, Cruz-Reséndiz A, Aguirre-Sampieri S,
Sampieri A, Vaca L. SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and
Implications of New Viral Variants. Front Immunol. 2021 Jul 12;12:701501.

Products Related to Delta Variant SARS-CoV-2 Spike RBD : SARS-CoV-2